545 related articles for article (PubMed ID: 26691983)
1. Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.
Gómez-Lechón MJ; Tolosa L; Donato MT
J Appl Toxicol; 2016 Jun; 36(6):752-68. PubMed ID: 26691983
[TBL] [Abstract][Full Text] [Related]
2. Current limitations and future opportunities for prediction of DILI from in vitro.
Funk C; Roth A
Arch Toxicol; 2017 Jan; 91(1):131-142. PubMed ID: 27766365
[TBL] [Abstract][Full Text] [Related]
3. Assessment of reactive metabolites in drug-induced liver injury.
Lee KS; Oh SJ; Kim HM; Lee KH; Kim SK
Arch Pharm Res; 2011 Nov; 34(11):1879-86. PubMed ID: 22139687
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the potential for drug-induced liver injury based on in vitro covalent binding to human liver proteins.
Usui T; Mise M; Hashizume T; Yabuki M; Komuro S
Drug Metab Dispos; 2009 Dec; 37(12):2383-92. PubMed ID: 19720731
[TBL] [Abstract][Full Text] [Related]
5. Evidence-based selection of training compounds for use in the mechanism-based integrated prediction of drug-induced liver injury in man.
Dragovic S; Vermeulen NP; Gerets HH; Hewitt PG; Ingelman-Sundberg M; Park BK; Juhila S; Snoeys J; Weaver RJ
Arch Toxicol; 2016 Dec; 90(12):2979-3003. PubMed ID: 27659300
[TBL] [Abstract][Full Text] [Related]
6. Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury.
Laifenfeld D; Qiu L; Swiss R; Park J; Macoritto M; Will Y; Younis HS; Lawton M
Toxicol Sci; 2014 Jan; 137(1):234-48. PubMed ID: 24136188
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Drug-Induced Liver Injury in HepG2 Cells Cultured with Human Liver Microsomes.
Choi JM; Oh SJ; Lee JY; Jeon JS; Ryu CS; Kim YM; Lee K; Kim SK
Chem Res Toxicol; 2015 May; 28(5):872-85. PubMed ID: 25860621
[TBL] [Abstract][Full Text] [Related]
8. Usefulness of in vitro combination assays of mitochondrial dysfunction and apoptosis for the estimation of potential risk of idiosyncratic drug induced liver injury.
Goda K; Takahashi T; Kobayashi A; Shoda T; Kuno H; Sugai S
J Toxicol Sci; 2016; 41(5):605-15. PubMed ID: 27665770
[TBL] [Abstract][Full Text] [Related]
9. Metabolic activation in drug-induced liver injury.
Leung L; Kalgutkar AS; Obach RS
Drug Metab Rev; 2012 Feb; 44(1):18-33. PubMed ID: 21939431
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles.
Zhang J; Doshi U; Suzuki A; Chang CW; Borlak J; Li AP; Tong W
Chem Biol Interact; 2016 Aug; 255():3-11. PubMed ID: 26581450
[TBL] [Abstract][Full Text] [Related]
11. Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening.
Gómez-Lechón MJ; Tolosa L
Arch Toxicol; 2016 Sep; 90(9):2049-2061. PubMed ID: 27325232
[TBL] [Abstract][Full Text] [Related]
12. Advances in Engineered Liver Models for Investigating Drug-Induced Liver Injury.
Lin C; Khetani SR
Biomed Res Int; 2016; 2016():1829148. PubMed ID: 27725933
[TBL] [Abstract][Full Text] [Related]
13. [Establishment of animal models of drug-induced liver injury and analysis of possible mechanisms].
Oda S; Yokoi T
Yakugaku Zasshi; 2015; 135(4):579-88. PubMed ID: 25832838
[TBL] [Abstract][Full Text] [Related]
14. Metabolic activation of hepatotoxic drug (benzbromarone) induced mitochondrial membrane permeability transition.
Shirakawa M; Sekine S; Tanaka A; Horie T; Ito K
Toxicol Appl Pharmacol; 2015 Oct; 288(1):12-8. PubMed ID: 26148448
[TBL] [Abstract][Full Text] [Related]
15. The primary role of hepatic metabolism in idiosyncratic drug-induced liver injury.
Amacher DE
Expert Opin Drug Metab Toxicol; 2012 Mar; 8(3):335-47. PubMed ID: 22288564
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of felbamate and other antiepileptic drug toxicity potential based on hepatic protein covalent binding and gene expression.
Leone AM; Kao LM; McMillian MK; Nie AY; Parker JB; Kelley MF; Usuki E; Parkinson A; Lord PG; Johnson MD
Chem Res Toxicol; 2007 Apr; 20(4):600-8. PubMed ID: 17381134
[TBL] [Abstract][Full Text] [Related]
17. Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury.
McEuen K; Borlak J; Tong W; Chen M
Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640208
[TBL] [Abstract][Full Text] [Related]
18. Relationship between structural alerts in NSAIDs and idiosyncratic hepatotoxicity: an analysis of spontaneous report data from the WHO database.
Jessurun N; van Puijenbroek E
Drug Saf; 2015 May; 38(5):511-5. PubMed ID: 25787329
[TBL] [Abstract][Full Text] [Related]
19. Minimizing DILI risk in drug discovery - A screening tool for drug candidates.
Schadt S; Simon S; Kustermann S; Boess F; McGinnis C; Brink A; Lieven R; Fowler S; Youdim K; Ullah M; Marschmann M; Zihlmann C; Siegrist YM; Cascais AC; Di Lenarda E; Durr E; Schaub N; Ang X; Starke V; Singer T; Alvarez-Sanchez R; Roth AB; Schuler F; Funk C
Toxicol In Vitro; 2015 Dec; 30(1 Pt B):429-37. PubMed ID: 26407524
[TBL] [Abstract][Full Text] [Related]
20. Measuring covalent binding in hepatotoxicity.
Devi SS; Palkar PS; Mehendale HM
Curr Protoc Toxicol; 2007 May; Chapter 14():Unit14.6. PubMed ID: 23045139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
